Form 4: Relay Therapeutics Executive Sells Shares to Cover Tax Obligations After RSU Vesting

A Relay Therapeutics executive, Peter Rahmer, sold shares to cover tax obligations following the vesting of restricted stock units (RSUs), while also receiving additional RSUs.

Summary

• Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics, sold a total of 45,464 shares of common stock across three transactions on January 28th, 29th and 30th, 2025.
• These sales were to cover income tax withholding obligations related to the vesting of restricted stock units (RSUs).
• The sales occurred at prices of $4.63, $4.55, and $4.42 per share respectively.
• Rahmer also acquired 139,141 shares through the vesting of RSUs on January 28, 2025.
• Following these transactions, Rahmer beneficially owns 402,431 shares of Relay Therapeutics common stock, including 253,604 shares underlying RSUs.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative for the company's outlook.

Positives

• The vesting of RSUs indicates that the executive is meeting performance criteria.
• The executive continues to hold a significant number of shares in the company.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors.

Risks

• Executive stock sales can sometimes create short-term downward pressure on the stock price.
• Continued sales by insiders could signal a lack of confidence in the company's future performance.

Industry Context

This type of transaction is common for executives who receive stock-based compensation, particularly around vesting dates. It is a routine part of executive compensation and not necessarily indicative of the company's performance or outlook.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a standard practice across the biotechnology and pharmaceutical industries.
• Many companies use RSUs as part of their compensation packages, leading to similar sales by executives at other firms such as Amgen, Regeneron, and Vertex Pharmaceuticals.
• The number of shares sold and the prices are within the typical range for such transactions.

Stakeholder Impact

• Shareholders may see a slight short-term impact on the stock price due to the sales.
• Employees may be interested in the details of executive compensation.

Key Dates

Keywords

Relay Therapeutics, RLAY, Peter Rahmer, insider trading, stock sale, restricted stock units, RSU, tax obligations, executive compensation